2[1]Packer M. The neurohumoral hypothesis: a theory to txplain the mechanism of disease progression in heart failure [J]. J A m Coll Cardiol, 1992, 20: 248 254.
3[2]Metra M, Nodari S, D'Aloia A, et al. A rationale for the use of β-blocker as standard treatment for heart failure[J]. Am Heart J,2000,139:511-521.
4[3]CIBIS-Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS-Ⅱ): a randomized trial[J]. Lancet, 1999,353:9-13.
5[4]MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure :Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [J]. Lancet, 1999,353:2001-2007.
6[5]Pareker M, Coats AJS, Fowler MB, et al. The effeet of carvedilol on morbidity and mortality in severe chronic heart failure [J]. N Eng J Med, 2001 , 344:1349-1355.
7[6]Doughty RN, Whalley GA, Gamble G, et al. On behalf of the Australia/New Zealand Heart Failure Research Collaborative Group, Left ventricular remodeJing with carvedilol in patients with congestive heart failure due to ischemic hearl dis ease[J]. J Am Coll Cardiol,1997 ,29 :1060-1066.
8[7]Lechat PP, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure : a meta-analysis of doublc-blind, placebo-controlled, randomized triala[J]. Circulation, 1998,98:1184-1191.
9[8]Bristow MR. Mechanism of action of β-blocking agents in heart failure [J]. Am J Cardiol, 1997,80:261-401.
10[9]The Beta-blocker Evaluation of Survival Trial Investigators. A trial of the beta blocker bucindolol in patients with advanced chronic heart failure[J]. N Eng J Med, 2001,344:1659-1667.
4Swirski F K,Nahrendorf M. Leukocyte behavior in atherosclerosis, my- ocardial infarction, and heart failure[J].Science, 2013 (6116 ): 16 ! - 166.
5Kim S H, Jeong S I, Huh J, et al. Amiodarone and catheter ablation as- cardiac resynchronization therapy for children with dilated cardiomyopathy and wolff-Parkinson-white syndrome[J]. Korean Circ J, 2013 ( 43 ):57-61.
